2. Biotechnology Market Sales of biologics amounted to $75 billion in 2007--just over 10 percent of the estimated $712 billion spent on prescription drugs last year. The combined market share of the top ten companies made up the bulk of those sales, coming to $61.4 billion. Sales of biotech drug grew 12.5 percent in 2007--twice as fast as the pharmaceutical market.
6. What Amgen has: Amgen has five of the 22 biotech blockbusters currently on the market--tied only with Roche. Marketed by Amgen and Wyeth, Enbrel tops this list as the world's bestselling biologic. The drug is indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosingspondylitis and moderate to severe plaque psoriasis. 1. Amgen
7. 1. Amgen What Amgen has: Enbrel, which competes with Remicade and Humira, brought in $5.2 billion in sales in 2007. Amgen saw sales of anemia drugs Arenesp and Epogen take a hit last year when the two garnered black box warnings for heart and vascular problems at high doses. Still, the second and eighth ranked blockbusters racked up $4.4 billion and $2.9 billion, respectively.
8. 1. Amgen What Amgen has: Neulasta and Neupogen (which treat a lack of certain white blood cells caused by cancer and chemo) round out the company's blockbusters. What to watch for: Amgen's next big up-and-coming drug is the osteoporosis treatment Denosumab. The drug has already been submitted for FDA review and, if approved, could bring in $2 billion to $3 billion in sales a year.
10. What they have: Roche's biggest biologic blockbuster is Rituxan, a rheumatoid arthritis and non-Hodgkins lymphoma remedy that raked in $2.2 billion in sales in 2007. Other blockbusters include the breast cancer treatment Herceptin ($1.2 billion) and Avastin ($2.4 billion), which is indicated for colon or rectal cancer, non-small cell lung cancer and HER2 negative breast cancer. Anemia drug Neorecormon and Lucentis for wet AMD round out Roche and Genentech's five biggest biologics. 2. Roche/Genentech
11. What to look for: Roche and Genentech have two new biologics in their late-stage pipeline. These are ocrelizumab, a monoclonal antibody for rheumatoid arthritis, and pertuzumab, another MAb for metastatic breast cancer. Additional indications for Avastin, Lucentis, Xolair are also in the works. 2. Roche/Genentech
12. 3. Johnson & Johnson 2007 Sales: $6.2 billion Market share: 8.4% CAGR: 3%
13. What they have: J&J's bestselling biologic is Remicade ($3.3 billion). Like the other anti-TNFs on this list, Remicade is approved for treating a host of immune diseases including plaque psoriasis, rheumatoid arthritis, psoriac arthritis, adult Crohn's disease, pediatricCrohn's disease, ulcerative colitis and ankylosingspondylitis. The company's only other biotech blockbuster is Procrit, which rounded up $2.2 billion in 2007. 3. Johnson & Johnson
14. What to look for: Johnson & Johnson has filed two biologics for approval. The psoriasis treatment ustekinumab is on the verge of winning FDA approval, having been backed by an FDA expert committee. Golimumab--a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosingspondylitis--is also awaiting an FDA decision. 3. Johnson & Johnson
16. What they have: Denmark-based Novo Nordisk's only blockbuster is NovoRapid, a fast-acting insulin product. 4. Novo Nordisk
17. What to look for: Novo Nordisk has three experimental treatments awaiting FDA approval. NovoMix is a Type 1 and 2 diabetes treatment, and Activelle is a low-dose hormone replacement therapy. Novo's most anticipated new therapy is the anti-diabetic drug Liraglutide. Liraglutide, which is a new class of antidiabetic medications called GLP-1 analogues, improved glucose control in late-stage clinical studies. The drug is also in Phase II testing for obesity. 4. Novo Nordisk
19. What they have: Eli Lilly has only one biologic blockbuster, despite the fact that it ranks fifth in overall biologic sales. Humalog, a Type 1 and 2 diabetes treatment, brought in $1.5 billion in sales in 2007. The company's big sellers include Forteo, a synthetic form of the natural occurring hormone that treats osteoporosis in men and women, and Xigris, a treatment for sepsis. About 25 percent of Lilly's 2007 sales came from biotech medicines. 5. Eli Lilly
20. 5. Eli Lilly What to look for: Biotech molecules also represent approximately one-third of the Lilly's current pipeline, including potential treatments targeting Alzheimer's disease, cancer and diabetes, according to a recent release. Lilly is working with MacroGenics to develop teplizumab, a humanized anti-CD3 monoclonal antibody for Type 1 diabetes which is in Phase III trials. The company is also partnered with Canadian biotech BioMS to develop dirucotide, a multiple sclerosis treatment.
22. What they have: Sanofi's top-selling biotech blockbuster is Lantus, a Type 1 and 2 diabetes treatment. The company also markets a host of vaccines through Sanofi Pasteur, the vaccine division of Sanofi-Aventis. 6. Sanofi-Aventis
23. What to look for: Currently, only 10 percent of the drugs Sanofi makes are biologics; the company wants to boost that number to 20 or 30 percent by 2012. Sanofi is collaborating with Regeneron on its drug Aflibercept (VEGF Trap), a cancer drug in late-stage trials for prostate and lung cancer. 6. Sanofi-Aventis
25. What they have: Abbott has two biotech blockbusters on the market. Humira, a monoclonal antibody, competes with Remicade and Enbrel. It's approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosingspondylitis, Crohn's disease, and plaque psoriasis. Synagis treats respiratory syncytial virus, the leading cause of hospitalization in babies under a year. 7. Abbott
26. 7. Abbott What to look for: Abbot is exploring new indications for Humira. It's also advancing a new biologic for autoimmune diseases. ABT-847 is in late-stage development for psoriasis and Crohne's disease. In addition, Abbott teamed up with Genentech in 2007 to develop and commercialize ABT-263 and ABT-869.
28. What they have: When Merck KGaA bought out Serono in 2006 it inherited Rebif, a top-selling multiple sclerosis drug. Merck is also one of three companies partnered on cancer drug Erbitux (along with ImClone and Bristo-Myers Squibb, which are not on this list). The drug is approved for head and neck and colorectal cancer. 8. Merck KGaA
29. What to look for: Merck KGaA has filed two additional indications for Erbitux and has a new formulation of Rebif in the works. The company is also conducting late-stage testing for atacicept, an experimental rheumatoid arthritis treatment. 8. Merck KGaA
31. What they have: Schering-Plough, which markets J&J's Remicade outside of the U.S, racked up $1.6 billion in sales in 2007. The company's pegylated interferon Hepatitis C injection Peg-Intron also brought in $911 million. 9. Schering-Plough
32. What to look for: Schering is partnered with J&J's Centocor on golimumabfor rheumatoid arthritis, ankylosingspondylitis, psoriatic arthritis and ulcerative colitis. The company beefed up it's biotech pipeline with the $14 billion acquisiton of OrganonBiosicences last year. 9. Schering-Plough
34. What they have: Wyeth's top-selling biologic is Enbrel, which it markets with Amgen. The monoclonal antibody is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosingspondylitis, psoriatic arthritis and chronic moderate to severe plaque psoriasis. 10. Wyeth
35. What to look for: Bapineuzumab--currently in Phase III development--is a humanized monoclonal antibody being investigated for the treatment of Alzheimer's disease and possibly glaucoma. 10. Wyeth
